Immune mobilization of autologous blood progenitor cells: Direct influence on the cellular subsets collected

Cytotherapy

Volumn 12, Issue 8, 2010, Pages 1013-1021

  Meehan, Kenneth R ^a   Talebian, Laleh ^a   Wu, Jillian ^a   Hill, John M ^a   Szczepiorkowski, Zbigniew M ^b   Sentman, Charles L ^c   Ernstoff, Marc S ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b Transfusion Medicine Service   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

effector cells; immune mobilization; interlukin 2; myeloma

Indexed keywords

CD34 ANTIGEN; CD56 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2;

ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; CAPILLARY LEAK SYNDROME; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DIARRHEA; DRUG DOSE ESCALATION; FATIGUE; FEMALE; FEVER; FLUID RETENTION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKAPHERESIS; MALE; MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; STEM CELL MOBILIZATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 78649297670     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.515580     Document Type: Article

References (31)

1. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant . 2009;43:181-95.
2. + cells mobilized by G-CSF. Bone Marrow Transplant . 1998;21:561-8.
3. Webb IJ, Eickhoff CE, Elias AD, Ayash LJ, Wheeler CA, Schwartz GN, et al. Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte-col-ony-stimulating factor: implications for yield of hematopoietic progenitor cell collections. Transfusion. 1996;36:160-7.
4. Demirer T, Buckner CD, Storer B, Lilleby K, Rowley S, Clift R, et al. Effect of different chemotherapy regimens on peripheral blood stem cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor. J Clin Oncol. 1997;15:684-90.
5. Talmadge JE, Reed EC, Kessinger A, Kuszynski CA, Perry GA, Gordy CL, et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant. 1996;17:101-9.
6. Verma UN, Mazumder A, Meehan KR. Interleukin-2 in combination with cyclophosphamide for peripheral blood stem cell mobilization. Cancer Res. 1997;38:3268a.
7. Gajewski J, Rondon G, Mehra R, et al. Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor for peripheral blood progenitor cell mobilization to growth factor alone for hematopoietic rescue after high dose chemotherapy. Blood. 1998;92:271a.
8. Ojeifo JO, Wu AG, Miao Y, Herscowtiz HB, Meehan KR. Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: kinetics, dose titration, and toxicity. Exp Hematol. 2000;28:451-9.
9. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A, et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood. 2001;98:579-85.
10. Kim H, Sohn HJ, Kim S, Lee JS, Kim WK, Suh C. Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma. Bone Marrow Transplant. 2006;37:1037-42.
11. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, et al. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin ' s lymphoma. Bone Marrow Transplant. 2004;33: 291-8.
12. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM, et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia. 2002;16:1311-8.
13. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood. 1998;91:3481-6.
14. Hiwase DK, Hiwase S, Bailey M, Bollard G, Schwarer AP. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14: 116-24.
15. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, et al. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autol-ogous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia. 2004;18:1085-92.
16. Condomines M, Quittet P, Lu ZY, Nadal L, Latry P, Lopez E, et al. Functional regulatory T cells are collected in stem cell autografts by mobilization with high-dose cyclophospha-mide and granulocyte colony-stimulating factor. J Immunol. 2006;176:6631-9.
17. Gazitt Y. Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells. 2000;18:390-8.
18. Barber A, Zhang T, Sentman CL. Immunotherapy with chi-meric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer. J Immunol. 2008;180:72-8.
19. Wu JY, Ernstoff MS, Hill JM, Cole B, Meehan KR. Ex vivo expansion of non-MHC-restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy. 2006;8: 141-8.
20. Barber A, Zhang T, Megli CJ, Wu J, Meehan KR, Sentman CL. Chimeric NKG2D receptor-expressing T cells as a novel immunotherapy for multiple myeloma. J Exp Heme. 2008; 36:1318-28.
21. Hill J, Wu J, Webber S, Ernstoff MS, Szczepiorkowski Z, Sentman C, Meehan KR. Immune mobilization with direct in-vivo effector response: favorable implications for post-transplant outcome. Blood. 2007;10:361a.
22. Meehan KR, Wu J, Ernstoff MS, Szczepiorkowski Z, Barber A, Sentman C. Development of a laboratory model for ex vivo expansion of multiple populations of effector T cells. Cyto-therapy. 2008;10:30-7.
23. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619-25.
24. + T cells after high-dose chemotherapy for metastatic breast cancer. J Clin Oncol. 2002;20:58-64.
25. Schiller GJ, Vescio R, Berenson J. Cytomegalovirus infection following transplantation of autologous CD34-selected progenitor cells. Blood. 2000;96:1194-5.
26. Sosman JA, Stiff P, Moss SM, Sorokin P, Martone B, Bayer R, et al. Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy: expansion of immune effectors within the stem-cell graft and post-stem-cell infusion. J Clin Oncol. 2001;19: 634-44.
27. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, et al. Induction of macrophage tumoricidal activity by granulocyte - macrophage colony-stimulating factor. Science. 1986;232:506-8.
28. Joshi SS, Lynch JC, Pavletic SZ, Tarantolo SR, Pirruccello SJ, Kessinger A, et al. Decreased immune functions of blood cells following mobilization with granulocyte colony-stimulating factor: association with donor characteristics. Blood. 2001;98: 1963-70.
29. Wing EJ, Magee DM, Whiteside TL, Kaplan SS, Shadduck RK. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. Blood. 1989;73:643-6.
30. Hock BD, Haring LF, Ebbett AM, Patton WN, McKenzie JL. Differential effects of G-CSF mobilization on dendritic cell subsets in normal allogeneic donors and patients undergoing autologous transplantation. Bone Marrow Transplant. 2002; 30:733-40.
31. Lonial S, Hicks M, Rosenthal H, Langston A, Redei I, Torre C, et al. A randomized trial comparing the combination of granulocyte - macrophage colony-stimulating factor plus gran-ulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant. 2004;10:848-57.